These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35585427)

  • 21. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL; Bensch G; Berdy GJ
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis.
    McLaurin E; Bergmann M; Narvekar A; Adewale A; Gomes P; Torkildsen G
    Clin Ophthalmol; 2017; 11():1089-1097. PubMed ID: 28652694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
    Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL
    Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
    Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.
    McMullin D; Clark D; Cavanagh B; Karpecki P; Brady TC
    Clin Ophthalmol; 2021; 15():3889-3900. PubMed ID: 34588761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.
    Abelson MB; Berdy GJ; Mundorf T; Amdahl LD; Graves AL;
    J Ocul Pharmacol Ther; 2002 Oct; 18(5):475-88. PubMed ID: 12419098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
    Clark D; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
    [No Abstract]   [Full Text] [Related]  

  • 32. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis.
    Castillo M; Scott NW; Mustafa MZ; Mustafa MS; Azuara-Blanco A
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009566. PubMed ID: 26028608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
    Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
    Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcaftadine for the prevention of itching associated with allergic conjunctivitis.
    Mahvan TD; Buckley WA; Hornecker JR
    Ann Pharmacother; 2012; 46(7-8):1025-32. PubMed ID: 22811343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.
    Mandell KJ; Clark D; Chu DS; Foster CS; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2020 Dec; 36(10):732-739. PubMed ID: 32955967
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis.
    James IG; Campbell LM; Harrison JM; Fell PJ; Ellers-Lenz B; Petzold U
    Curr Med Res Opin; 2003; 19(4):313-20. PubMed ID: 12841924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model.
    Ackerman S; D'Ambrosio F; Greiner JV; Villanueva L; Ciolino JB; Hollander DA
    J Asthma Allergy; 2013; 6():43-52. PubMed ID: 24109191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber.
    Jacobs RL; Ramirez DA; Rather CG; Andrews CP; Jupiter DC; Trujillo F; Shulman DG
    Ann Allergy Asthma Immunol; 2017 Jan; 118(1):86-93.e2. PubMed ID: 28007090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis.
    McLaurin EB; Evans D; Repke CS; Sato MA; Gomes PJ; Reilly E; Blender N; Silva FQ; Vantipalli S; Metzinger JL; Gibson A; Goldstein MH
    Am J Ophthalmol; 2021 Sep; 229():288-300. PubMed ID: 33773984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.